- Split View
-
Views
-
Cite
Cite
Da Kuang, Jochen Weile, Nishka Kishore, Maria Nguyen, Alan F Rubin, Stanley Fields, Douglas M Fowler, Frederick P Roth, MaveRegistry: a collaboration platform for multiplexed assays of variant effect, Bioinformatics, Volume 37, Issue 19, October 2021, Pages 3382–3383, https://doi.org/10.1093/bioinformatics/btab215
- Share Icon Share
Abstract
Multiplexed assays of variant effect (MAVEs) are capable of experimentally testing all possible single nucleotide or amino acid variants in selected genomic regions, generating ‘variant effect maps’, which provide biochemical insight and functional evidence to enable more rapid and accurate clinical interpretation of human variation. Because the international community applying MAVE approaches is growing rapidly, we developed the online MaveRegistry platform to catalyze collaboration, reduce redundant efforts, allow stakeholders to nominate targets and enable tracking and sharing of progress on ongoing MAVE projects.
MaveRegistry service: https://registry.varianteffect.org. MaveRegistry source code: https://github.com/kvnkuang/maveregistry-front-end.
1 Introduction
Diagnostic genetic testing frequently yields extremely rare or previously unseen genetic variants, amongst which it can be difficult to identify the subsets of pathogenic and benign variants. Indeed, within the ClinVar repository of clinically observed human variation (Landrum et al., 2018), over 50% of missense variants are classified as ‘variants of uncertain significance’ (VUS) (Weile and Roth, 2018; Starita et al., 2017).
Functional assays provide evidence that can assist variant interpretation (Richards et al., 2015; Brnich et al., 2019). However, such results can arrive weeks or even years after initial discovery of a variant. Multiplexed assays of variant effect (MAVEs) can provide more economical and consistently measured evaluation of variant function than single-variant functional assays (Weile and Roth, 2018; Starita et al., 2017; Brnich et al., 2019). By testing nearly all possible single-nucleotide or amino acid variants in a genomic region of interest, MAVEs can provide ‘proactive’ evidence both for previously observed variants and for variants that will be observed in years to come.
The number of MAVE studies has grown in recent years (Weile and Roth, 2018; Esposito et al., 2019), and includes nearly 100 research labs. Coordination efforts are being launched at the national (e.g. NIH’s Impact of Genomic Variation on Function Consortium) and international (e.g. Atlas of Variant Effects Alliance) levels. To facilitate collaboration and communication at this scale, we created the MaveRegistry. This resource aims to serve diverse stakeholders, including interested researchers, clinicians, patients, patient advocates and funders.
MaveRegistry enables users to: (ii) browse posted MAVE studies; (ii) nominate targets for variant effect mapping; (iii) share progress on ongoing or published MAVE studies; and (iv) follow progress updates from research teams. We expect that the MaveRegistry platform will reduce unintentional competition, promote collaboration and provide efficient communication about systematic variant effect mapping studies, while attracting additional interest from the general public and funding bodies.
2 Access projects via a role-based model
‘Real time’ sharing of progress on unpublished projects, which remains rare in academia, can be beneficial (Fischer and Zigmond, 2010). For example, progress-sharing in generating gene-knockout mouse embryonic stem cells (Austin et al., 2004) has helped to inform and avoid duplicated efforts. However, researchers may fear being ‘scooped’ by a competitor (Theologis and Davis, 2004). To encourage progress-sharing for MAVE studies, we designed a role-based model (Fig. 1A) to enable users providing project updates to control who can access their information. These roles are ‘public’, ‘member’, ‘follower’ and ‘funder’.
For MAVE projects marked as ‘published’, anyone can (with a ‘public’ role in Fig. 1A) use MaveRegistry, without logging in, to access all information. Such records include a brief project summary and links to publications and data.
Users can create an account and thus become ‘members’ (see Fig. 1A). Member researchers can deposit their ongoing or published MAVE projects. Any member can request permission to view or even edit posted MAVE projects. If approved by the depositor to ‘follow’ a project, members (now with a ‘follower’ role in Fig. 1A) can view project details. Members may also request permission to follow research teams. Followers of either projects or teams will receive notifications about status changes in relevant projects. Members affiliated with funding agencies may take a ‘funder’ role (Fig. 1A), granting access to the (optionally disclosed by depositors) funding needs for each MAVE project. Figure 1B exemplifies the information visible to users with different roles.
3 Register and manage MAVE projects
Members can deposit ongoing or published variant effect mapping projects. If a genomic region (i.e. target element) has not been previously submitted, the submitter will be prompted for basic information, including target name, type (i.e. protein-coding gene or other genomic region) and relevant organism. The depositor then provides contact information for a project lead, to be shared with other members to facilitate direct communication. A research team is named for each project, enabling a ‘view projects by research team’ function. To describe a project’s status, depositors can select terms from a controlled vocabulary of project activity. For each activity, the start and (if appropriate) end date can be entered. A brief free-text progress summary, aided by template questions, can also be provided. Depositors can also provide links to external sources, e.g. relevant publications, code repositories, online lab notebooks or protocol resources.
When members make ‘follow’ requests, the relevant depositors are notified. Depositors can review the reason-to-follow message, approve or reject each follow request, provide edit access (e.g. to collaborators), remove followers or transfer ownership of their projects to other members.
4 Nominate targets for variant effect mapping
Diverse stakeholders, e.g. patients, patient advocates, clinicians or researchers with an interest in the fundamentals of sequence-structure relationships, may wish to nominate new targets for MAVE studies. MaveRegistry therefore provides a nomination interface, and enables other members to ‘upvote’ or ‘downvote’ nominations. When the nominated target is a human protein-coding gene, users may link to MaveQuest, an online resource for identifying potential functional assays and other information about clinical relevance (Kuang et al., 2020).
Acknowledgements
The authors appreciate L. Muffley, F. Chardon and other members of the Center for the Multiplexed Assessment of Phenotype for advice, and thank early adopters R. Hartmann-Petersen, J. Kitzman, J. Fraser, W. Coyote-Maestas, L. Starita and M. Hurles.
Funding
This work was supported by the National Human Genome Research Institute of the National Institutes of Health Center of Excellence in Genomic Science [HG004233 and HG010461]; the Canada Excellence Research Chairs Program; a Canadian Institutes of Health Foundation grant; and the One Brave Idea Foundation.
Conflict of Interest: none declared.